Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate

Hengstman, GJD; De Bleecker, JL; Feist, E; Vissing, J; Denton, CP; Manoussakis, MN; Jensen, HS; van Engelen, BGM; van den Hoogen, FHJ

dc.contributor.author	Hengstman, GJD	en
dc.contributor.author	De Bleecker, JL	en
dc.contributor.author	Feist, E	en
dc.contributor.author	Vissing, J	en
dc.contributor.author	Denton, CP	en
dc.contributor.author	Manoussakis, MN	en
dc.contributor.author	Jensen, HS	en
dc.contributor.author	van Engelen, BGM	en
dc.contributor.author	van den Hoogen, FHJ	en
dc.date.accessioned	2014-03-01T01:57:34Z
dc.date.available	2014-03-01T01:57:34Z
dc.date.issued	2008	en
dc.identifier.issn	0014-3022	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28434
dc.subject	myositis	en
dc.subject	open-label trial	en
dc.subject	methotrexate	en
dc.subject	anti-TNF therapy	en
dc.subject.classification	Clinical Neurology	en
dc.subject.classification	Neurosciences	en
dc.subject.other	NECROSIS-FACTOR-ALPHA	en
dc.subject.other	INFLAMMATORY MYOPATHIES	en
dc.subject.other	RECEPTORS	en
dc.title	Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2008	en
heal.abstract	Background/Aims: To determine the efficacy of infliximab combined with weekly methotrexate in drug-naive recent-onset dermatomyositis and polymyositis. Methods: A multi-centre open-label controlled trial was conducted. Disease activity was assessed using patient's and physician's disease activity assessment, manual muscle testing (MMT), hand-held dynamometry, and serum CK. The primary objective was to assess the efficacy using MMT after a period of 26 weeks. Results: The study was terminated prematurely because of a low inclusion rate and a high drop-out rate due to disease progression and the occurrence of an infusion reaction. The few patients who did reach the primary endpoint showed improvement in all aspects studied. Conclusion: Infliximab combined with weekly methotrexate might be safe and well tolerated in a small subgroup of patients with drug-naive recent-onset myositis. At present, we do not advocate the use of this treatment because treatment response cannot be predicted beforehand. Copyright (C) 2008 S. Karger AG, Basel.	en
heal.publisher	KARGER	en
heal.journalName	EUROPEAN NEUROLOGY	en
dc.identifier.isi	ISI:000253371700009	en
dc.identifier.volume	59	en
dc.identifier.issue	3-4	en
dc.identifier.spage	159	en
dc.identifier.epage	163	en